WHAT IS HT-002?
HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.
HT-002 is at the preclinical stage of development.
Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.